ModifiedUnitedHealthcarePolicy CS052NJ.R

Hearing Aids and Devices Including Wearable, Bone-Anchored, and Semi-Implantable (for New Jersey Only)

Medical policy governing coverage and medical necessity of hearing aids and related devices (wearable, bone-anchored, semi-implantable, and totally implanted) for UnitedHealthcare Community Plan members in New Jersey.

Policy Summary

PayerUnitedHealthcare

PolicyHearing Aids and Devices Including Wearable, Bone-Anchored, and Semi-Implantable (for New Jersey Only)

Policy CodePolicy CS052NJ.R

Change TypeCPT code additions

Effective DateAugust 1, 2025

Next Review DateN/A

Key ActionSubmit prior authorization with audiometry, word recognition scores, age, and device-eligibility documentation when requesting implantable or transcutaneous bone conduction devices.

SourceLink

POLICY UPDATE CHANGES

Updated list of applicable CPT codes to reflect quarterly edits; added 0951T, 0952T, 0953T, 0954T, and 0955T.

New Jersey onlystate-specific application

List includedcoding appendix present

Several listedunproven/not medically necessary items

5+new CPT tokens added

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

FDA clearance years cited

Coverage Criteria and Evidence Summary

Medically necessary device categories

Covered when used according to FDA labeled indications for individuals who are not candidates for air-conduction hearing aids:

Covered device categories: Bilateral fully or partially implantable bone-anchored Hearing Aids for conductive or mixed hearing loss in both ears; Bilateral or unilateral bone conduction Hearing Aids utilizing a headband or adhesive (without osseointegration); Semi-implantable electromagnetic Hearing Aid for sensorineural hearing loss; Unilateral fully or partially implantable bone-anchored Hearing Aids for conductive or mixed hearing loss in one or both ears; Unilateral fully or partially implantable bone-anchored Hearing Aids for sensorineural hearing loss in one ear.

Devices must be used per FDA labeled indications.

Unproven / Not medically necessary

Not medically necessary due to insufficient evidence of efficacy:

Not medically necessary devices: Intraoral bone conduction Hearing Aids (eg, SoundBite); Laser or light-based Hearing Aids (eg, Earlens Contact Hearing Device); Totally implanted middle ear hearing systems (eg, Esteem).

These device classes are described in the policy as unproven and not medically necessary due to insufficient evidence of efficacy.

Evidence summaries informing coverage

Findings from the included literature (observational studies, systematic reviews, and RCTs) informing coverage considerations:

Evidence supporting non-implantable air-conduction hearing aids: Air-conduction hearing aids improve hearing-specific and general health-related quality of life and listening ability in adults with mild to moderate hearing loss (Cochrane review of RCTs).

Supports first-line use of air-conduction aids when indicated.

Non-implantable bone conduction devices for pediatric conductive loss: Multiple cohort and case series demonstrate significant audiologic gains and high satisfaction with softband or adhesive bone conduction devices in infants and children with conductive or unilateral microtia/atresia; useful as early intervention or a trial prior to implantation.

Supports trialing non-implantable devices in pediatric populations.

Partially/fully implantable BCHAs and transcutaneous devices: Systematic reviews and meta-analyses report improved audiologic outcomes and patient satisfaction for selected patients with conductive/mixed loss or single-sided deafness, but evidence quality ranges from low to very low and comparative superiority versus alternatives is not definitive.

General coverage conditions (device-specific)

Coverage stance is mixed and device-specific; devices may be considered medically necessary for select patients who meet device labeling and professional society recommendations.

General device eligibility: Patient meets device-specific FDA labeling indications (age, audiologic thresholds, word recognition where specified) AND conventional amplification is inadequate, not tolerated, or contraindicated.see device labeling

AAO-HNS supports active middle ear implants and bone conduction devices when conventional aids are unsuitable.

Bone-anchored device criteria

Bone-anchored and partially implantable bone conduction devices — common explicit indications in FDA labeling:

Bone conduction / BAHA indications: Conductive or mixed hearing loss with bone-conduction pure tone average (PTA BC) better than device-specific thresholds OR single-sided deafness when patient cannot or will not use an AC CROS; bilateral implantation for symmetric losses as defined in labeling.BC PTA thresholds and symmetry definitions per device labeling

Multiple BAHA, Bonebridge, Osia, and Sophono models list explicit BC threshold cutoffs, age limits, and symmetry criteria in FDA labeling.

Device-specific inclusion criteria

Device-specific FDA indications and typical inclusion criteria (summarized):

Age: Patient meets device-specific minimum age (examples: Cochlear Baha Attract ≥5 years; Bonebridge and Osia systems ≥12 years; Earlens ≥18 years).age per device

See device labeling for exact age requirement.

Hearing type: Patient has conductive or mixed hearing loss, or single-sided deafness (SSD) where benefit from bone conduction is expected.

Devices have device-specific PTA BC eligibility thresholds.

PTA BC thresholds: PTA bone-conduction thresholds must meet device-specific cutoffs (examples provided in labeling: ≤45 dB HL for BP100/Bonebridge in some processors; ≤55 dB HL for certain BP110/Osia settings; ≤65 dB HL for Cordelle II/Baha SuperPower; ADHEAR ≤25 dB HL).device-specific

The policy lists intraoral bone conduction hearing aids, laser or light‑based hearing aids, and totally implanted middle ear hearing systems together as device classes that are considered unproven and not medically necessary because of insufficient evidence of efficacy. These categories are distinguished from bone‑anchored and other implantable or non‑implantable bone conduction devices that may be covered when used per FDA labeled indications and device‑specific criteria.

The available literature provides insufficient high‑quality evidence to support routine coverage of intraoral bone conduction hearing aids. Studies are limited by small sample sizes, short follow‑up, lack of randomization, absence of concurrent control groups, and selective attrition, which prevent definitive conclusions about effectiveness despite some positive single‑arm reports (eg, SoundBite series).

Across the device classes identified as unproven or uncertain, the evidence is characterized by single‑arm studies, small cohorts, short follow‑up, and lack of concurrent control groups. Several reports note device‑related withdrawals, heterogeneous outcome measures, and conflicting results between studies, limiting confidence in net clinical benefit and comparative effectiveness. These limitations are the primary basis for classifying some devices as investigational or not medically necessary.

Although the SoundBite intraoral system received FDA clearance, manufacturing ceased after the manufacturer filed bankruptcy in 2015; the device is no longer available despite prior clearance, which affects its clinical availability and relevance to coverage decisions.

For clarity: intraoral bone conduction devices, laser/light‑based hearing aids, and totally implanted middle ear systems are identified in this policy as device classes with insufficient or uncertain evidence to support routine coverage. Coverage implications are device‑specific: devices with adequate, higher‑quality evidence and that meet FDA labeled indications and documented device eligibility may be considered medically necessary; the listed classes above are not supported by sufficient evidence.

Available evidence for the Bonebridge bone conduction implant is described as low‑ to very‑low quality, with studies at high risk of bias and no randomized controlled trials. Because comparative evidence is indirect and sometimes contradictory, no definitive conclusions about superiority over other treatment options can be drawn from current studies.

Totally implantable middle ear hearing systems (eg, Carina, Esteem) lack robust randomized controlled trial evidence and are represented mainly by single‑arm series and systematic reviews of small, heterogeneous studies. Findings across reports are mixed and include device failures, explants, and variable complication rates, resulting in insufficient high‑quality evidence to establish clear effectiveness for broad populations.

Coverage determinations based on this policy must be reconciled with applicable federal, state, and contractual requirements. The policy provides guidance on device classes and evidence but does not override specific benefit terms; when conflicts exist, the federal, state, or contractual requirements govern.

Coding Appendix and Audiologic Thresholds

Bone Anchored Hearing Aids (BAHA) and related CPT/T codesCPT

69710	Implantation or replacement of electromagnetic bone conduction hearing device in temporal bone.
69714	Implantation, osseointegrated implant, skull; with percutaneous attachment to external speech processor.
69716	Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, within the mastoid and/or resulting in removal of less than 100 sq mm surface area of bone deep to the outer cranial cortex.
69717	Replacement (including removal of existing device), osseointegrated implant, skull; with percutaneous attachment to external speech processor.
69719	Replacement (including removal of existing device), osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, within the mastoid and/or involving a bony defect less than 100 sq mm surface area of bone deep to the outer cranial cortex.
69729	Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside of the mastoid and resulting in removal of greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex.
69730	Replacement (including removal of existing device), osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside the mastoid and involving a bony defect greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex.
92590	Hearing aid examination and selection; monaural.
92591	Hearing aid examination and selection; binaural.
92592	Hearing aid check; monaural.

1–10 of 19

1/2

BAHA HCPCS/L-codesHCPCS

L8690	Auditory osseointegrated device, includes all internal and external components.
L8691	Auditory osseointegrated device, external sound processor, excludes transducer/actuator, replacement only, each.
L8693	Auditory osseointegrated device abutment, any length, replacement only.
L8694	Auditory osseointegrated device, transducer/actuator, replacement only, each.

Fitting/testing and wearable device HCPCS/V and miscellaneous codesmixed

S0618	Audiometry for hearing aid evaluation to determine the level and degree of hearing loss.
V5010	Assessment for hearing aid.
V5011	Fitting/orientation/checking of hearing aid.
V5014	Repair/modification of a hearing aid.
V5020	Conformity Evaluation.
V5264	Ear mold/insert, not disposable, any type.
V5265	Ear mold/insert, disposable, any type.
V5275	Ear impression, each.
L8692	Auditory osseointegrated device, external sound processor, used without osseointegration, body worn, includes headband or other means of external attachment.
V5030	Hearing aid, monaural, body worn, air conduction.

1–10 of 23

1/3

Regulatory / informational (no billing codes listed in this section)mixed

No codes listed

Applicable CPT codes addedCPT

0951T	Totally implantable active middle ear hearing implant; initial placement, including mastoidectomy, placement of and attachment to sound processor.
0952T	Totally implantable active middle ear hearing implant; revision or replacement, with mastoidectomy and replacement of sound processor.
0953T	Totally implantable active middle ear hearing implant; revision or replacement, without mastoidectomy and replacement of sound processor.
0954T	Totally implantable active middle ear hearing implant; replacement of sound processor only, with attachment to existing transducers.
0955T	Totally implantable active middle ear hearing implant; removal, including removal of sound processor and all implant components.

Degree of Hearing Loss — numeric categories

Normal-10 to 15 dB HL

Slight16 to 25 dB HL

Mild26 to 40 dB HL

Moderate41 to 55 dB HL

Moderately severe56 to 70 dB HL

Severe71 to 90 dB HL

Profound

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Equipment upgrades treated as new requests

Equipment upgrades are treated as new requests. A change in the member’s medical condition or equipment needs requires submission of the same clinical criteria and documentation as an initial request; upgrades are equivalent to a new service and will be reviewed under the same standards.

Equipment upgrades require the same criteria and documentation as a new device request.
Treat upgrade requests as new services for prior authorization and benefit determination.

Prior Authorization

Prior authorization recommended for implantable/transcutaneous devices

Prior authorization is recommended for implantable and transcutaneous bone conduction and middle ear hearing devices due to variable evidence quality, device-specific eligibility, and potential complication risks. PA helps ensure appropriate patient selection and documentation prior to surgery or device implantation.

Recommended to obtain PA for fully or partially implantable bone-anchored hearing aids, active and semi‑implantable middle ear implants, and active/transcutaneous bone conduction systems.

Background and Policy Scope

Wearable air‑conduction hearing aids remain the standard treatment for hearing loss that cannot be corrected medically or surgically. Bone conduction and bone‑anchored hearing aids are alternatives for patients who are not candidates for air‑conduction devices (for example, congenital ear canal malformations); semi‑implantable electromagnetic devices and other implantable options may be considered when used according to FDA labeling and documented device‑specific eligibility.

Definitions and Terminology

Conductive Hearing Loss — definition

DefinitionOccurs when sound is not conducted efficiently through the outer ear canal to the eardrum and the ossicles of the middle ear

Clinical effectUsually involves a reduction in sound level or the ability to hear faint sounds

ReversibilityThis type of hearing loss can often be corrected medically or surgically

Degree of Hearing Loss — categorized

Normal-10 to 15 dB HL

Slight16 to 25 dB HL

Mild

Policy Revision History

08/01/2025code_updateLatest

Updated list of applicable CPT codes to reflect quarterly edits; added 0951T, 0952T, 0953T, 0954T, and 0955T.

Policy Summary

PayerUnitedHealthcare

PolicyHearing Aids and Devices Including Wearable, Bone-Anchored, and Semi-Implantable (for New Jersey Only)

Policy CodePolicy CS052NJ.R

Change TypeCPT code additions

Effective DateAugust 1, 2025

Next Review DateN/A

Key ActionSubmit prior authorization with audiometry, word recognition scores, age, and device-eligibility documentation when requesting implantable or transcutaneous bone conduction devices.

SourceLink

On This Page

Considerable heterogeneity and limited comparative trials temper conclusions.

Complications and device-specific risks: Reported complication rates vary across device classes: for pTCBIs minor and major event incidence rates have been reported (eg, minor events and low major-event incidence), and some devices report device-related withdrawals; studies are often single-arm with short follow-up.

Balance audiologic benefit versus complication risk in coverage decisions.

Insufficient/uncertain evidence: Some device classes (intraoral bone conduction, laser/light-based, certain totally implantable middle ear systems) have limited or low-quality evidence, lack randomized trials, or have conflicting findings, limiting definitive conclusions about effectiveness across populations.

May be considered investigational or not medically necessary pending stronger evidence.

Use the numeric threshold tied to the specific device per FDA labeling.

Symmetry for bilateral fitting: For bilateral implantation, bone-conduction thresholds should be symmetric between ears (average difference <10 dB or <15 dB at individual frequencies).symmetry per device

Applies to bilateral fitting indications.

SSD contralateral hearing: For SSD indications the hearing ear's PTA air-conduction must be ≤20 dB HL (measured at 0.5, 1, 2, and 3 kHz).≤20 dB HL

Applies to devices with SSD indication (eg, Baha, Bonebridge, Osia, Sophono).

Prior experience recommended: Prior experience with appropriately fitted air-conduction or bone-conduction hearing aids is recommended before implantation for several devices.

FDA labeling commonly recommends trial of conventional amplification or non-implantable BCDs prior to implantation.

Audiologic threshold examples from device labeling

Vibrant Soundbridge AC ranges (example by frequency)500 Hz: 30–65 dB; 1000 Hz: 40–75 dB; 1500 Hz: 45–80 dB; 2000 Hz: 45–80 dB; 3000 Hz: 50–85 dB; 4000 Hz: 50–85 dB

BAHA/BP100 ABP indications (example PTA BC)PTA bone-conduction threshold better than or equal to 45 dB HL (measured at 0.5, 1, 2, and 3 kHz)

ADHEAR (non-implantable) PTA BC examplePTA bone-conduction threshold better than or equal to 25 dB HL (measured at 0.5, 1, 2, and 3 kHz)

Pure tone average bone-conduction threshold (PTA BC) — device-specific examples

BP100 / Bonebridge examplePTA BC ≤ 45 dB HL (measured at 0.5, 1, 2, and 3 kHz) — e.g., BP100/Bonebridge/Baha BP100 use

Osia / BP110 power examplePTA BC ≤ 55 dB HL for some processors (eg, BP110/Osia indications)

Cordelle II / Baha 5 SuperPower examplePTA BC ≤ 65 dB HL for high-power processors (Cordelle II / Baha 5 SuperPower)

ADHEAR example (low-threshold device)PTA BC ≤ 25 dB HL (ADHEAR system indication)

Contralateral normal hearing (SSD indications)

Contralateral normal hearing for SSDPTA air-conduction threshold of the hearing ear ≤ 20 dB HL (measured at 0.5, 1, 2, and 3 kHz)

Devices citing this requirementSophono/Otomag, Bonebridge, Osia, BAHA indications list PTA AC ≤20 dB HL for the contralateral ear in SSD indications

Measurement frequencies specifiedPTA measured at 0.5, 1, 2, and 3 kHz

Symmetry threshold between ears

Average BC symmetry criterionAverage bone-conduction difference between ears < 10 dB (measured at 0.5, 1, 2, and 3 kHz)

Per-frequency allowanceLess than 15 dB difference allowed at individual frequencies

ApplicabilityUsed to determine suitability for bilateral fitting or bilateral implantation per device labeling

Verify PA requirements with benefit contract prior to scheduling procedures.

Documentation Required

Prior authorization: submit audiology and device-eligibility documentation

Submit complete audiologic and device-eligibility documentation with any prior authorization request. Documentation should support the clinical need and device-specific eligibility criteria and include objective audiometric data and trial history when applicable.

Include pure-tone audiometry (PTA) thresholds, bone conduction (BC) thresholds, and air conduction (AC) thresholds measured at standard frequencies.
Provide word recognition scores (recorded material), speech discrimination results, and any validated patient-reported outcome measures used.
Supply device-specific eligibility data (e.g., age limits, PTA/BC thresholds, device labeling criteria) and prior trial documentation (see related items).

Billing Rule

CPT code updates — verify PA requirements

Verify CPT/HCPCS code and prior authorization requirements prior to submission. CPT code updates may affect PA requirements; confirm benefit contract and PA rules for newly added codes.

Policy update added CPT codes 0951T–0955T (see Applicable Codes/Policy History).
Inclusion of a code in the policy or code list does not guarantee coverage — coverage subject to federal, state, or contractual benefit terms.

Denial Risk

Denial risk for unproven devices

Devices or indications listed as unproven or not medically necessary in this policy may be denied. FDA clearance alone is informational and is not sufficient to guarantee coverage.

Examples of unproven/not medically necessary devices: intraoral bone conduction hearing aids, laser/light-based hearing aids, totally implanted middle ear systems (per policy list).
Expect potential denials when submitted indications lack sufficient evidence or fall outside labeled/contractual coverage.

Denial Risk

Insufficient high-quality comparative evidence

Insufficient high-quality comparative evidence exists for some implantable/transcutaneous systems. Lack of randomized controlled trials and definitive comparative studies may impact medical necessity determinations.

Evidence often consists of cohort studies, case series, and indirect comparisons with heterogeneous outcomes.
When comparative effectiveness is unclear, PA reviewers may request additional justification or deny when criteria are unmet.

Billing Rule

Coding and benefit determination

Coding and benefit determination: listing of procedure or diagnosis codes in this policy is for reference only and does not ensure coverage or payment. Benefit coverage is governed by applicable federal, state, or contractual requirements and may require use of third‑party tools.

Inclusion of a code in policy does not imply coverage or reimbursement rights.
UnitedHealthcare may use external tools (e.g., InterQual) to assist in benefit administration; always check member’s plan terms.

Documentation Required

Document device-specific eligibility and audiologic test results

Document device-specific eligibility and audiologic test results clearly with PA submissions. Provide the specific thresholds, scores, age criteria, and any device labeling requirements that justify the chosen device per FDA labeling and manufacturer indications.

Report PTA and BC thresholds (include frequencies used and averaging method) and word recognition score with test materials specified.
Attach manufacturer/FDA device labeling or summary that documents age limits, PTA/BC thresholds, and any recommended prior aid experience.
If a device’s labeling recommends prior experience with appropriately fitted air- or bone-conduction aids, document that experience or the reason it was not feasible.

Note

Reference benefit requirements

Reference benefit requirements and applicable laws when making coverage decisions. Federal, state, or contractual benefit requirements override this policy when conflicts exist.

Before applying this policy, check the member’s federal, state, or contractual benefit terms — they govern in the event of a conflict.
UnitedHealthcare reserves the right to modify policies and may rely on federal/state law or contractual language for final determination.

Prior Authorization

Trial with non-implantable BCHA

Trial with non-implantable bone conduction hearing aids (headband or adhesive/softband) is recommended, especially for children and when determining candidacy for implantable systems. Non-implantable trials can inform expected benefit and support device selection.

Use headband, softband, or adhesive (e.g., ADHEAR) systems as an initial trial prior to surgical implantation, particularly in pediatric patients.
Document trial duration, objective aided audiologic results, and patient-reported benefit to support subsequent implant requests.

Documentation Required

Experience with non-implantable aids recommended

Experience with appropriately fitted non-implantable air- or bone-conduction hearing aids is recommended prior to implantation when device labeling advises. Document prior hearing-aid use or provide clinical rationale if prior experience was not possible.

If FDA labeling or manufacturer guidance recommends prior experience with air‑ or bone‑conduction aids (e.g., Bonebridge, Osia), include documentation of that experience in the PA.
When experience with conventional amplification is clinically inappropriate (e.g., anatomy precludes air-conduction aid use), provide supporting clinical documentation.

Moderate41 to 55 dB HL

Moderately severe56 to 70 dB HL

Severe71 to 90 dB HL

Profound91 dB HL or more

Sensorineural Hearing Loss (SNHL) — definition

DefinitionOccurs when there is damage to the inner ear (cochlea) or auditory nerve pathways; usually not correctable medically or surgically

Typical permanenceMost SNHL is permanent

Implication for devicesOften managed with amplification (hearing aids) or implantable devices when amplification insufficient

Mixed Hearing Loss — definition

DefinitionCombination of conductive and sensorineural components (damage in outer/middle ear plus inner ear or auditory nerve)

Clinical noteManagement may require addressing both conductive and sensorineural elements; device selection depends on predominant component

TestingIdentified by mixed air- and bone-conduction thresholds on audiometry

Laser or Light-Based Hearing Aids — definition

TechnologyConverts sound to infrared light transmitted from a BTE processor to a tympanic membrane transducer

Example deviceEarlens Contact Hearing Device (CHD)

MechanismLight pulses are converted into vibrations applied directly to the tympanic membrane

Totally Implantable Middle Ear Hearing Systems — definition

DefinitionFully implanted systems comprising implanted sound processor, sensor, and driver that transmit signals to the inner ear without external microphones/speakers

Example deviceEsteem prosthetic hearing restoration device

PowerDevice may use a maintenance-free battery (example: Esteem up to nine years)

Non-implantable Bone Conduction Devices — definition

DefinitionExternal bone conduction devices retained by headband or adhesive that transmit sound via bone conduction without surgery

Common usesEarly intervention in infants/children, trials prior to implantation, or for patients who cannot/will not undergo surgery

ExamplesBAHA headband/softband, ADHEAR system

Active/Passive Transcutaneous Bone Conduction Implants — definition

DefinitionPartially implanted devices using magnetic coupling across intact skin to transmit vibrations to implanted bone conduction hardware

Intended benefitReduce skin-penetrating complications versus percutaneous devices while providing bone conduction stimulation

Evidence noteSystematic reviews report improved audiologic outcomes and high patient satisfaction but variable quality of evidence

Intraoral Bone Conduction Hearing Aid (IOBC) — definition

DefinitionDental-mounted transducer transmitting sound via teeth/jaw to the cochlea for single-sided deafness

Example deviceSoundBite (IOBC)

Availability noteManufacturing ceased after manufacturer bankruptcy; device no longer available despite prior FDA clearance

Single-Sided Deafness (SSD) — definition

DefinitionUnilateral sensorineural deafness in one ear with normal hearing in the other ear

Normal-hearing criterionContralateral PTA air-conduction threshold ≤ 20 dB HL (measured at 0.5, 1, 2, and 3 kHz)

Device applicabilitySSD indications appear in BAHA, Bonebridge, Osia, ADHEAR labeling when patients cannot/will not use AC CROS

Symmetrical bone-conductive thresholds — definition (0.5,1,2,3 kHz)

Measurement frequencies0.5, 1, 2, and 3 kHz (some sources include 4 kHz for averages)

Symmetry criterionLess than a 10 dB average difference between ears (measured at 0.5, 1, 2, and 3 kHz)

Per-frequency allowanceOr less than a 15 dB difference at individual frequencies

Symmetrical bone-conductive thresholds — restated

Restated symmetry definitionAverage BC difference < 10 dB between ears (0.5,1,2,3 kHz) or < 15 dB at individual frequencies

Use caseApplies to bilateral fitting indications in BAHA, Bonebridge, Osia labeling

Measurement noteSome device labeling references include 4 kHz for bilateral symmetry calculations

Single-sided deafness (SSD) / Normal hearing definition

SSD / Normal hearing definitionSSD: profound sensorineural deafness in one ear with normal hearing in the contralateral ear; normal hearing defined as PTA AC ≤ 20 dB HL (measured at 0.5, 1, 2, and 3 kHz)

Devices referencing this definitionBAHA family, Bonebridge, ADHEAR, Osia labeling include this SSD contralateral hearing requirement

Measurement frequenciesPTA measured at 0.5, 1, 2, and 3 kHz